(Q48331568)

10 February 2018

title

Sorafenib in hepatocellular carcinoma: prospective study on adverse events, quality of life, and related feasibility under daily conditions (English)

1 reference

10 February 2018

main subject

hepatocellular carcinoma

1 reference

8

1 reference

10 February 2018

Mario Rizzetto

9

object named as

Mario Rizzetto

1 reference

10 February 2018

author name string

Paola Rita Brunocilla

1

1 reference

10 February 2018

Franco Brunello

2

1 reference

10 February 2018

Patrizia Carucci

3

1 reference

10 February 2018

Silvia Gaia

4

1 reference

10 February 2018

Emanuela Rolle

5

1 reference

10 February 2018

Alessandro Cantamessa

6

1 reference

10 February 2018

Anna Castiglione

7

1 reference

10 February 2018

publication date

22 December 2012

1 reference

10 February 2018

published in

Medical Oncology

1 reference

10 February 2018

volume

30

1 reference

10 February 2018

issue

1

1 reference

10 February 2018

page(s)

345

1 reference

10 February 2018

The changing pattern of epidemiology in hepatocellular carcinoma

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0345-2

Prognosis of hepatocellular carcinoma: the BCLC staging classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0345-2

Management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0345-2

Management of hepatocellular carcinoma: An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0345-2

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0345-2

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0345-2

Transection of the oesophagus for bleeding oesophageal varices

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0345-2

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0345-2

Toxicity and response criteria of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0345-2

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0345-2

Efficacy and safety of sorafenib in advanced hepatocellular carcinoma under daily practice conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0345-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0345-2

Impact of sorafenib on health-related quality of life in Japanese patients with metastatic renal cell carcinoma: a prospective evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0345-2

Beyond traditional outcomes: improving quality of life in patients with renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0345-2

Sorafenib: a clinical and pharmacologic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0345-2

Assessment of patient-reported clinical outcome in pancreatic and other hepatobiliary cancers: the FACT Hepatobiliary Symptom Index

21 January 2018

1 reference

12 December 2020

Measuring health-related quality of life in patients with hepatobiliary cancers: the functional assessment of cancer therapy-hepatobiliary questionnaire

1 reference

12 December 2020

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

1 reference

12 December 2020

Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer

1 reference

12 December 2020

10.1007/S12032-012-0345-2

Identifiers

DOI

1 reference

10 February 2018

1 reference

10 February 2018